Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Cancer Gene Ther. 2009 Oct 2;17(4):244–255. doi: 10.1038/cgt.2009.70

Figure 6.

Figure 6

Cisplatin causes enhancement of tumor vascular leakiness and synergizes with oncolytic Sindbis vector in cancer therapy. Starting on day 0, daily treatments of cisplatin (4 mg/Kg or 12mg/m2 compared with maximum tolerated dose of 100 mg/m2 in human) were i.p. injected into SCID mice bearing s.c. N2a tumors. The last cisplatin treatment was administrated on day 4. (a) To visualize vascular leakiness, AngioSense 750 (0.66 nmol) was i.v. injected on day 1 and imaged on day 2. (b) RC-Sindbis/Fluc was i.v. injected on day 0 and day 2. Luciferase activities in tumors, indicating active vector propagation, were monitored on day 3. (c) Relative tumor growth curves of different treatment groups. P value was generated by two-way ANOVA of trend.